Department of Rehabilitation, Versilia Hospital AUSL Toscana Nord Ovest, Camaiore, Lucca, Italy -
Bioengineering Rehabilitation Laboratory, Auxilium Vitae Rehabilitation Center, Volterra, Pisa, Italy -
Eur J Phys Rehabil Med. 2018 Aug;54(4):536-544. doi: 10.23736/S1973-9087.17.04815-8. Epub 2017 Sep 4.
Spasticity is a muscle disorder associated with upper motor neuron syndrome occurring in neurological disorders, such as stroke, multiple sclerosis, spinal cord injury and others. It influences the patient's rehabilitation, interfering with function, limiting independence, causing pain and producing secondary impairments, such as contractures or other complications. Due to the heterogeneity of clinical signs of spasticity, there is no agreement on the most appropriate assessment and measurement modality for the evaluation of treatment outcomes.
The aim of this article is to propose the use of new robotic devices for upper-limb spasticity assessment and describe the most relevant measures of spasticity which could be automatically assessed by using a technologically advanced device.
Observational pilot study.
The treatment was provided in a Rehabilitation Centre where the device was located and the subjects were treated in an outpatients setting.
Five post-stroke patients, age range 19-79 years (mean age 61, standard deviation [SD]±25) in their chronic phase.
A new robotic device able to automatically assess upper-limb spasticity during passive and active mobilization has been developed. The elbow spasticity of five post stroke patients has been assessed by using the new device and by means of the Modified Ashworth Scale (MAS). After the first assessment, subjects were treated with botulin toxin injections, and then underwent 10 sessions of robotic treatments. After the treatment, subjects spasticity was assessed by using the robotic device and the MAS Score.
In four out of five patients, the botulin toxin injection and robotic treatment resulted in the improvement of the MAS Score; in three patients the robotic measures were able to detect the MAS changes. In one subject botulin toxin was not effective and the robotic device was able to detect the lack of effectiveness.
By using the robotic device some spasticity parameters can be continuously recorded during the rehabilitation treatment in order to objectively measure the effectiveness of the interventions provided.
The standardized evaluation parameters recorded using robotic devices may provide several advantages: 1) the measures for spasticity assessment can be monitored during every rehabilitation session (even during each movement); 2) these measurements are able to highlight even small changes; 3) the recovery plateau can be detected early thus avoiding further rehabilitation sessions; and 4) these measurements can reduce the assessment bias in multicenter studies.
痉挛是一种与上运动神经元综合征相关的肌肉障碍,发生在神经系统疾病中,如中风、多发性硬化症、脊髓损伤等。它影响患者的康复,干扰功能,限制独立性,引起疼痛,并产生继发性损伤,如挛缩或其他并发症。由于痉挛的临床体征具有异质性,因此对于评估治疗效果,没有关于最合适的评估和测量方式的共识。
本文旨在提出使用新型机器人设备来评估上肢痉挛,并描述可以通过使用技术先进的设备自动评估的最相关的痉挛测量指标。
观察性试点研究。
治疗在康复中心进行,设备位于该中心,患者在门诊接受治疗。
5 名年龄在 19-79 岁(平均年龄 61 岁,标准差±25)的慢性期脑卒中后患者。
开发了一种新的机器人设备,能够在被动和主动运动期间自动评估上肢痉挛。使用新设备和改良 Ashworth 量表(MAS)对 5 名脑卒中后患者的肘部痉挛进行评估。首次评估后,患者接受肉毒毒素注射治疗,然后接受 10 次机器人治疗。治疗后,使用机器人设备和 MAS 评分评估患者的痉挛程度。
在 5 名患者中,有 4 名患者的肉毒毒素注射和机器人治疗导致 MAS 评分改善;在 3 名患者中,机器人测量能够检测到 MAS 的变化。在 1 名患者中,肉毒毒素无效,机器人设备能够检测到无效。
通过使用机器人设备,可以在康复治疗期间连续记录一些痉挛参数,以便客观地测量所提供干预措施的效果。
使用机器人设备记录的标准化评估参数可能具有以下几个优势:1)可以在每次康复治疗过程中(甚至在每次运动中)监测痉挛评估的测量值;2)这些测量值能够突出显示微小的变化;3)能够及早发现恢复平台期,从而避免进一步的康复治疗;4)这些测量值可以减少多中心研究中的评估偏差。